Objective Overactive bladder (OAB) is an emerging condition that significantly impacts the quality of life and daily routine of millions of people. It is characterized by urinary urgency, increased urinary frequency and nocturia. OAB is extremely frequent, affecting more than 500 million people worldwide and its prevalence is expected to increase by 9,2% by 2018. Despite being a widely spread affection, currently there is no effective treatment in the market, and the ones available are associated to adverse reactions and drug-to-drug interactions, leading to up to 88,6% of dropout cases. As a consequence, the market trend is shifting from prescription drugs to products from natural origin. In the recent years, there has been a strong increase in the market for herbal medicinal products in Europe which is looking forward to bio-based solutions. These facts open up a clear opportunity for alternative solutions like the ones developed by SagaMedica, an Icelandic company with 17 years of experience in the field of natural product manufacturing. At SagaMedica we have developed SagaPro+, the first new natural product for improving OAB symptoms in decades. It is made from an extract of the leaves of Angelica archangelica, whose activity on the bladder was discovered by SagaMedica’s research team. We have developed a harvesting, extraction and manufacturing process system that has been kept sustainable and eco-friendly. SagaPro+ provides several advantages compared to current alternatives: 1) Highly effective product, as it has been reported by clinical trials; 2) It has no adverse effects nor drug-to-drug interactions; and 3) It is based in a natural product from a sustainable production and harvesting system, contributing to Europe´s bio-based economy. All these reasons brought high interest of various companies, with cooperation discussions already progressing with three strong players. Several Support Letters prove this market demand. Fields of science engineering and technologymechanical engineeringmanufacturing engineeringmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health scienceshealth sciencesnutritionsocial scienceseconomics and businesseconomicsbioeconomysocial scienceseconomics and businesseconomicssustainable economy Programme(s) H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme H2020-EU.3.2.4. - Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy H2020-EU.3.2.1. - Sustainable agriculture and forestry H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.2.2. - Sustainable and competitive agri-food sector for a safe and healthy diet Topic(s) SMEInst-07-2016-2017 - Stimulating the innovation potential of SMEs for sustainable and competitive agriculture, forestry, agri-food and bio-based sectors Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator SAGAMEDICA - HEILSUJURTIR EHF Net EU contribution € 50 000,00 Address KROKHALSI 5D 110 REYKJAVIK Iceland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ísland Ísland Höfuðborgarsvæði Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
